Suppr超能文献

BCL2在浸润性乳腺癌女性患者中的预后价值

Prognostic Value of BCL2 in Women Patients with Invasive Breast Cancer.

作者信息

Ayadi E-Z, Cherif B, Ben Hamed Y, Mokni M, Rebai A, Ayadi H, Jlidi R

机构信息

Procédés de criblage moléculaire et cellulaire, Centre of Biotechnology of Sfax B.P K.3038 Sfax, Tunisia.

Patholab Private CytoPathology Laboratory R. du Caire, Cité Jardin Sfax,Tunisia.

出版信息

Asian Pac J Cancer Prev. 2018 Dec 25;19(12):3557-3564. doi: 10.31557/APJCP.2018.19.12.3557.

Abstract

Background: Breast cancers are heterogeneous, making it essential to recognize several biomarkers for cancer outcome predictions especially in young women where the classical prediction parameters are not suitable. The goal from this study is to evaluate the impact of B cell lymphoma 2 (BCL2), P53 and Ki-67 proteins expression on survival in young women patients with invasive ductal carcinoma. Patients and methods: Samples and clinical data from 238 patients were collected between 2003 and 2017. They were selected according to 2 criteria: age ≤40 years old and most of them are affected by an Invasive Ductal Carcinoma. We evaluated BCL2, P53 and ki-67 expression by immunochemistry test, and then we assessed correlations of these biomarkers expression with patient’s clinicopathological characteristics and survival. Results: Triple negative breast cancer group showed a high frequency among our cohort but we emphasize an almost equitable distribution among all molecular groups. Contrary to other studies which reported that luminal A was correlated with better prognosis, our analysis demonstrated that luminal A is correlated with the Scarff, Bloom and Richardson (SBR) grading 2 or SBR grading 3. To better investigate the prognosis, we analyze three biomarkers known by their impact on physiopathology behavior on breast cancer BCL2, ki-67and P53. BCL2 is the more relevant one, it was correlated with molecular subtypes (p=0.0012) and SBR grading (p=0.0016). BCL2 seems to be the good prognostic biomarker related to survival (p=0.004) with a protective role among patients when endocrine therapy is not provided and Lymph Node (LN) involvement is positive (p=0.021, p=0.000 respectively). Conclusions: The classical prognostic parameters based mainly on the molecular classification in breast cancer seem insufficient in the case of young women. BCL2 protein expression analysis provides a better prognostic value. BCL2 should be clinically associated in current practice when young women specimens are diagnosticated.

摘要

背景

乳腺癌具有异质性,因此识别多种生物标志物对于预测癌症预后至关重要,尤其是在经典预测参数不适用的年轻女性中。本研究的目的是评估B细胞淋巴瘤2(BCL2)、P53和Ki-67蛋白表达对年轻女性浸润性导管癌患者生存的影响。

患者和方法

收集了2003年至2017年间238例患者的样本和临床数据。他们根据两个标准进行选择:年龄≤40岁,且大多数患者患有浸润性导管癌。我们通过免疫化学测试评估BCL2、P53和Ki-67的表达,然后评估这些生物标志物表达与患者临床病理特征和生存的相关性。

结果

三阴性乳腺癌组在我们的队列中占比很高,但我们强调所有分子组之间的分布几乎均衡。与其他报道管腔A型与较好预后相关的研究相反,我们的分析表明管腔A型与斯卡夫、布鲁姆和理查森(SBR)分级2级或SBR分级3级相关。为了更好地研究预后,我们分析了三种因其对乳腺癌生理病理行为的影响而闻名的生物标志物BCL2、Ki-67和P53。BCL2是更相关的一种,它与分子亚型(p=0.0012)和SBR分级(p=0.0016)相关。BCL2似乎是与生存相关的良好预后生物标志物(p=0.004),在内分泌治疗未提供且淋巴结(LN)受累为阳性的患者中具有保护作用(分别为p=0.021,p=0.000)。

结论

在年轻女性中,主要基于分子分类的经典预后参数似乎并不充分。BCL2蛋白表达分析具有更好的预后价值。在年轻女性标本诊断时,BCL2应在当前实践中与临床相关联。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验